P2RY12 and chronic kidney disease: Second, 95% of our patients were under clopidogrel treatment, however, some evidence has shown that new P2Y12 inhibitors, like ticagrelor or prasugrel, are more effective in preventing MACE events in CKD patients compared to clopidogrel [46].